[基于网络药理学和肠道微生物群的Poria cocos的喘缓解作用]
Qi-Mei Tie1, Meng-Nan Zeng1, Bei-Bei Zhang1
1Henan University of Chinese Medicine Zhengzhou 450046, China Henan Engineering Research Center for Traditional Chinese Medicine Development Zhengzhou 450046, China.
概括
波利亚可可斯通过调节免疫反应和肠道微生物群,有效地减轻小鼠的喘症状. 这种传统药物可以减少炎症并恢复肠道微生物的平衡,为喘提供潜在的自然治疗方法.
科学领域:
- 免疫学和微生物学
- 药理学和传统医学的医学.
背景情况:
- 喘是一种慢性呼吸道疾病,其特点是气道炎症和高反应性.
- 肠道微生物群 (GM) 失生症越来越被认为是导致喘发展和严重性的因素.
- 波利亚可可斯是一种传统的草药,具有潜在的免疫调节和抗炎性质.
研究的目的:
- 为了研究Poria cocos.的减轻喘效果.
- 探索涉及免疫炎症和肠道微生物群调节的潜在机制.
- 为 Poria cocos 在喘管理中的临床应用提供科学基础.
主要方法:
- 使用卵胺 (OVA) 敏感化建立了一种小鼠喘模型.
- 在不同剂量中服用Poria cocos,并评估喘表型,肺功能和炎症标志物 (IgE,IFN-γ,IL-4,IL-10).
- 通过16S rRNA测序分析了肺组织病理,与呼吸道炎症相关的基因表达,血清/支气管洗液炎症因素,以及肠道微生物群组成.
主要成果:
- 在喘小鼠中,Poria cocos治疗显著降低了咳频率,喘息和肺组织病理损伤.
- 它通过降低IgE和IL-4调节免疫反应,并增加IL-10和IFN-γ水平,从而维持免疫平衡.
- 波里亚可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可可
结论:
- 波利亚可可斯通过调节免疫-炎症通路,显示出显著的喘缓解作用.
- 它通过减少特定的促炎细菌来恢复肠道微生物平衡,从而减轻全身炎症.
- 这些发现支持Poria cocos作为喘的潜在治疗剂,通过免疫和肠道微生物系统的调节起作用.
更多相关视频
08:34Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
1.4K
03:25Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment
Published on: December 27, 2024
1.7K
相关概念视频
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.2K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.2K
01:20Asthma: Pathogenesis and Management
1.5K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.5K
01:26Asthma-II: Pathophysiology and Classification
4.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.7K
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
1.9K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.9K
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
2.0K
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
2.0K
01:24Antiasthma Drugs: Methylxanthines
1.9K
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
1.9K